Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3258678 | 0.81 | MAPT (0.50) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A | |
| SCHEMBL18273024 | 0.80 | ALDH1A1 (0.49) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A | |
| SCHEMBL969167 | 0.79 | ALDH1A1 (0.66) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A | |
| SCHEMBL28018647 | 0.78 | LMNA (0.56) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A | |
| Hydrochloric Acid SCHEMBL28787382 | 0.78 | ALDH1A1 (0.63) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A | |
| SCHEMBL24858578 | 0.76 | ALDH1A1 (0.61) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A | |
| SCHEMBL2749466 | 0.76 | ALDH1A1 (0.56) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A | |
| SCHEMBL2750562 | 0.76 | MAPT (0.46) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A | |
| SCHEMBL103727 | 0.76 | LMNA (1.00) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A | |
| SCHEMBL102844 | 0.76 | SMN1; SMN2 (1.00) | ALDH1A1LMNASMN1; SMN2PDPK1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107417705-B | Imidazo [2,1-b] benzothiazole compound and its synthetic method | 湘潭大学 | 2019-07-02 | — | — | CN | claimed |
| CN-107417705-A | Imidazo [2,1 b] benzothiazole compound and its synthetic method | 湘潭大学 | 2017-12-01 | — | — | CN | claimed |
| CN-119528901-B | Thiazole compound, dessumo and/or deubiquitinase inhibitor, and preparation methods and applications thereof | Shanghai tongji hospital (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4652154-A1 | NOVEL ALPK1 INHIBITORS | Pyrotech (Beijing) Biotechnology Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| EP-4631948-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-10-15 | — | — | EP | disclosed |
| EP-4626888-A1 | COMPOUNDS | Redx Pharma Limited (GB) | 2025-10-08 | — | — | EP | disclosed |
| EP-4606803-A1 | KRAS G12D DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-12365676-B2 | Heterocyclic compounds and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4554580-A1 | NEW ANTIBIOTIC COMPOUNDS | Université Côte d'Azur (FR) | 2025-05-21 | — | — | EP | disclosed |
| US-5635607-A | BLUE OR VIOLET COLOR DYE FOR DYEING PAPER, TEXTILES | CIBA-GEIGY CORPORATION (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0679691-A2 | Cationic or basic aminobenzthiazole dyestuffs | CIBA-GEIGY AG (CH) | 1995-11-02 | — | — | EP | disclosed |
| US-5424439-A | Process for the preparation of 2-amino-4-nitrobenzothiazole derivatives and intermediates | RHONE-POULENC RORER S.A. (FR) | 1995-06-13 | — | — | US | disclosed |
| US-5120872-A | Textile dyeing | CIBA-GEIGY CORPORATION (US) | 1992-06-09 | — | — | US | disclosed |
| US-4994563-A | Dyeing, printing cellulose, silk, wool, synthetic polyamides; colorfastness | CIBA-GEIGY CORPORATION (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0349486-A2 | Azo dyes, their preparation and their use | CIBA-GEIGY AG (CH) | 1990-01-03 | — | — | EP | disclosed |
| US-4118384-A | DIAZOTIZATION | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4041024-A | FOR POLYAMIDES AND POLYURETHANES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-08-09 | — | — | US | disclosed |
| US-3933423-A | Azoic dyeing of leather | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | ALDH1A1 1000/4885LMNA 4245/4885SMN1; SMN2 2361/4885 |
| US-12365676-B2 | Heterocyclic compounds and uses thereof | TP53, KRAS, HRAS | ALDH1A1 3377/4885LMNA 2529/4885SMN1; SMN2 1460/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 908/4885LMNA 3592/4885SMN1; SMN2 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.